• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在散发性表现的嗜铬细胞瘤或腹部副神经节瘤患者中种系突变的流行情况:瑞典西部的一项基于人群的研究。

Prevalence of germline mutations in patients with pheochromocytoma or abdominal paraganglioma and sporadic presentation: a population-based study in Western Sweden.

机构信息

Department of Surgery, Sahlgrenska University Hospital, 413 45 Gothenburg, Sweden.

出版信息

World J Surg. 2012 Jun;36(6):1389-94. doi: 10.1007/s00268-012-1430-6.

DOI:10.1007/s00268-012-1430-6
PMID:22270996
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3348434/
Abstract

BACKGROUND

Germline mutations in the susceptibility genes RET, SDHB, SDHD, and VHL have been reported in 7.5-24% of patients with pheochromocytoma (Pheo) or paraganglioma (PGL) and sporadic presentation. The purpose of the present study was to establish population-based data on the frequency of germline mutations in patients with apparently sporadic Pheo or abdominal PGL in Western Sweden.

METHODS

From the Swedish National Cancer Registry, all patients with Pheo or PGL in Western Sweden (population 1.72 million) registered between 1958 and 2009 were identified (n = 256). Patients were characterized using register data, hospital records, and clinical interviews. All living patients with Pheo or abdominal PGL and sporadic presentation (n = 81) were invited to genetic screening; 71 patients accepted. Germline mutations were investigated by using direct sequencing for point mutations in RET, SDHB, SDHD, and VHL, and multiplex ligation-dependent probe amplification for gross deletions in SDHB, SDHC, SDHD, and VHL. Plasma or urinary metanephrines and/or urinary catecholamines were used for biochemical follow-up.

RESULTS

The prevalence of germline mutations was 5.6%. Mutations were only seen in RET (n = 1) and SDHB (n = 3). Notably, in the patients with SDHB mutations, no malignant phenotype was observed during a mean follow-up of 23.3 years.

CONCLUSIONS

The frequency of germline mutations in patients with apparently sporadic Pheo and abdominal PGL in Western Sweden was lower than in previous studies. Variations in reported frequencies of germline mutations in patients with clinically sporadic Pheo/PGL may reflect geographical differences or patient selection.

摘要

背景

在散发性表现的嗜铬细胞瘤(Pheo)或副神经节瘤(PGL)患者中,已经报道了易感基因 RET、SDHB、SDHD 和 VHL 的种系突变,其发生率为 7.5-24%。本研究的目的是建立瑞典西部散发性 Pheo 或腹部 PGL 患者中种系突变的频率的基于人群的数据。

方法

从瑞典国家癌症登记处,确定了 1958 年至 2009 年期间在瑞典西部登记的所有 Pheo 或 PGL 患者(人口 172 万)(n=256)。使用登记数据、医院记录和临床访谈对患者进行了特征描述。所有具有散发性表现的 Pheo 或腹部 PGL 且仍存活的患者(n=81)均被邀请进行遗传筛查;71 名患者接受了邀请。通过对 RET、SDHB、SDHD 和 VHL 的点突变进行直接测序,以及对 SDHB、SDHC、SDHD 和 VHL 的大片段缺失进行多重连接依赖性探针扩增,来检测种系突变。使用血浆或尿液间甲肾上腺素和/或尿液儿茶酚胺进行生化随访。

结果

种系突变的患病率为 5.6%。突变仅见于 RET(n=1)和 SDHB(n=3)。值得注意的是,在具有 SDHB 突变的患者中,在平均 23.3 年的随访中没有观察到恶性表型。

结论

在瑞典西部具有散发性表现的 Pheo 和腹部 PGL 患者中,种系突变的频率低于以前的研究。在具有临床散发性 Pheo/PGL 的患者中报道的种系突变频率的差异可能反映了地域差异或患者选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5cc/3348434/7ec6a19f6242/268_2012_1430_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5cc/3348434/7ec6a19f6242/268_2012_1430_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5cc/3348434/7ec6a19f6242/268_2012_1430_Fig1_HTML.jpg

相似文献

1
Prevalence of germline mutations in patients with pheochromocytoma or abdominal paraganglioma and sporadic presentation: a population-based study in Western Sweden.在散发性表现的嗜铬细胞瘤或腹部副神经节瘤患者中种系突变的流行情况:瑞典西部的一项基于人群的研究。
World J Surg. 2012 Jun;36(6):1389-94. doi: 10.1007/s00268-012-1430-6.
2
Germline mutations and genotype-phenotype correlations in patients with apparently sporadic pheochromocytoma/paraganglioma in Korea.韩国散发性嗜铬细胞瘤/副神经节瘤患者的胚系突变及基因型-表型相关性
Clin Genet. 2014 Nov;86(5):482-6. doi: 10.1111/cge.12304. Epub 2013 Nov 15.
3
Germline mutations and genotype-phenotype correlation in Asian Indian patients with pheochromocytoma and paraganglioma.亚洲印度裔嗜铬细胞瘤和副神经节瘤患者的种系突变及基因型-表型相关性
Eur J Endocrinol. 2016 Oct;175(4):311-23. doi: 10.1530/EJE-16-0126.
4
Genetic testing in pheochromocytoma or functional paraganglioma.嗜铬细胞瘤或功能性副神经节瘤的基因检测
J Clin Oncol. 2005 Dec 1;23(34):8812-8. doi: 10.1200/JCO.2005.03.1484.
5
Genetic mutation screening in an italian cohort of nonsyndromic pheochromocytoma/paraganglioma patients.意大利非综合征性嗜铬细胞瘤/副神经节瘤患者队列中的基因突变筛查
Ann N Y Acad Sci. 2006 Aug;1073:156-65. doi: 10.1196/annals.1353.016.
6
Novel SDHB and TMEM127 Mutations in Patients with Pheochromocytoma/Paraganglioma Syndrome.嗜铬细胞瘤/副神经节瘤综合征患者中的新型SDHB和TMEM127突变
Pathol Oncol Res. 2016 Oct;22(4):673-9. doi: 10.1007/s12253-016-0050-0. Epub 2016 Mar 9.
7
Candidate gene mutation analysis in bilateral adrenal pheochromocytoma and sympathetic paraganglioma.双侧肾上腺嗜铬细胞瘤和交感神经节旁神经瘤的候选基因突变分析
Endocr Relat Cancer. 2007 Jun;14(2):453-62. doi: 10.1677/ERC-06-0044.
8
Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing.遗传性嗜铬细胞瘤和副神经节瘤的突变:为什么所有患者都应接受基因检测。
Ann Surg Oncol. 2013 May;20(5):1444-50. doi: 10.1245/s10434-013-2942-5. Epub 2013 Mar 20.
9
Rationalization of genetic testing in patients with apparently sporadic pheochromocytoma/paraganglioma.对明显散发型嗜铬细胞瘤/副神经节瘤患者进行基因检测的合理性分析
Horm Metab Res. 2009 Sep;41(9):672-5. doi: 10.1055/s-0029-1202814. Epub 2009 Apr 2.
10
Is genetic screening indicated in apparently sporadic pheochromocytomas and paragangliomas?在貌似散发性的嗜铬细胞瘤和副神经节瘤中是否需要进行基因筛查?
Surgery. 2011 Dec;150(6):1194-201. doi: 10.1016/j.surg.2011.09.024.

引用本文的文献

1
Global epidemiology of pheochromocytoma: a systematic review and meta-analysis of observational studies.嗜铬细胞瘤的全球流行病学:观察性研究的系统评价和荟萃分析
J Endocrinol Invest. 2025 Jul 2. doi: 10.1007/s40618-025-02639-9.
2
Cytoplasmic HIF-2α as tissue biomarker to identify metastatic sympathetic paraganglioma.细胞质 HIF-2α 作为组织生物标志物,用于识别转移性交感神经副神经节瘤。
Sci Rep. 2023 Jul 18;13(1):11588. doi: 10.1038/s41598-023-38606-8.
3
exon 1 deletion: A recurrent germline mutation in Colombian patients with pheochromocytomas and paragangliomas.

本文引用的文献

1
Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma.外显子组测序发现 MAX 突变是遗传性嗜铬细胞瘤的病因。
Nat Genet. 2011 Jun 19;43(7):663-7. doi: 10.1038/ng.861.
2
Validation of the multiplex ligation-dependent probe amplification (MLPA) technique for the determination of HER2 gene amplification in breast cancer.用于确定乳腺癌中HER2基因扩增的多重连接依赖探针扩增(MLPA)技术的验证。
Diagn Mol Pathol. 2011 Mar;20(1):11-7. doi: 10.1097/PDM.0b013e3181ed7832.
3
SDHA is a tumor suppressor gene causing paraganglioma.
外显子1缺失:哥伦比亚嗜铬细胞瘤和副神经节瘤患者中一种反复出现的种系突变。
Front Genet. 2023 Jan 4;13:999329. doi: 10.3389/fgene.2022.999329. eCollection 2022.
4
Mutational Signature and Transcriptomic Classification Analyses as the Decisive Diagnostic Tools for a Cancer of Unknown Primary.突变特征和转录组分类分析作为未知原发癌的决定性诊断工具。
JCO Precis Oncol. 2018 Jul 30;2. doi: 10.1200/PO.18.00002. eCollection 2018.
5
MYO5B mutations in pheochromocytoma/paraganglioma promote cancer progression.MYO5B 突变在嗜铬细胞瘤/副神经节瘤中促进肿瘤进展。
PLoS Genet. 2020 Jun 8;16(6):e1008803. doi: 10.1371/journal.pgen.1008803. eCollection 2020 Jun.
6
Clinical Practice Guidance: Surveillance for phaeochromocytoma and paraganglioma in paediatric succinate dehydrogenase gene mutation carriers.临床实践指南:琥珀酸脱氢酶基因突变携带者的嗜铬细胞瘤和副神经节瘤监测。
Clin Endocrinol (Oxf). 2019 Apr;90(4):499-505. doi: 10.1111/cen.13926. Epub 2019 Jan 29.
7
New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification.《嗜铬细胞瘤和副神经节瘤的新视角:迈向分子分类》
Endocr Rev. 2017 Dec 1;38(6):489-515. doi: 10.1210/er.2017-00062.
8
Precision medicine in pheochromocytoma and paraganglioma: current and future concepts.嗜铬细胞瘤和副神经节瘤的精准医学:当前与未来概念
J Intern Med. 2016 Dec;280(6):559-573. doi: 10.1111/joim.12507. Epub 2016 May 10.
9
Bilateral carotid paraganglioma: surgery and radiotherapy.双侧颈动脉体瘤:手术与放疗
Clin Med Insights Case Rep. 2014 Jul 3;7:53-7. doi: 10.4137/CCRep.S14223. eCollection 2014.
10
Integrative genetic characterization and phenotype correlations in pheochromocytoma and paraganglioma tumours.嗜铬细胞瘤和副神经节瘤的综合遗传特征及表型相关性
PLoS One. 2014 Jan 22;9(1):e86756. doi: 10.1371/journal.pone.0086756. eCollection 2014.
琥珀酸脱氢酶(SDHA)是一种抑癌基因,可导致副神经节瘤。
Hum Mol Genet. 2010 Aug 1;19(15):3011-20. doi: 10.1093/hmg/ddq206. Epub 2010 May 18.
4
Germline mutations in TMEM127 confer susceptibility to pheochromocytoma.TMEM127 种系突变可导致嗜铬细胞瘤易感性。
Nat Genet. 2010 Mar;42(3):229-33. doi: 10.1038/ng.533. Epub 2010 Feb 14.
5
An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis.一种用于检测携带种系SDHB、SDHC或SDHD基因突变的副神经节瘤和嗜铬细胞瘤患者的免疫组织化学方法:一项回顾性和前瞻性分析。
Lancet Oncol. 2009 Aug;10(8):764-71. doi: 10.1016/S1470-2045(09)70164-0. Epub 2009 Jul 1.
6
The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas.在一系列大量前瞻性嗜铬细胞瘤患者中进行琥珀酸脱氢酶基因检测。
J Clin Endocrinol Metab. 2009 Aug;94(8):2817-27. doi: 10.1210/jc.2008-2504. Epub 2009 May 19.
7
Semi-automated unidirectional sequence analysis for mutation detection in a clinical diagnostic setting.用于临床诊断环境中突变检测的半自动单向序列分析。
Genet Test Mol Biomarkers. 2009 Jun;13(3):381-6. doi: 10.1089/gtmb.2008.0096.
8
Genetics of pheochromocytoma and paraganglioma in Spanish patients.西班牙患者嗜铬细胞瘤和副神经节瘤的遗传学
J Clin Endocrinol Metab. 2009 May;94(5):1701-5. doi: 10.1210/jc.2008-2756. Epub 2009 Mar 3.
9
Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas.对一大群患有嗜铬细胞瘤和/或功能性或非功能性副神经节瘤的意大利患者进行临床指导的基因筛查。
J Clin Endocrinol Metab. 2009 May;94(5):1541-7. doi: 10.1210/jc.2008-2419. Epub 2009 Feb 17.
10
Denaturing high performance liquid chromatography detection of SDHB, SDHD, and VHL germline mutations in pheochromocytoma.变性高效液相色谱法检测嗜铬细胞瘤中SDHB、SDHD和VHL基因种系突变
J Surg Res. 2009 Nov;157(1):55-62. doi: 10.1016/j.jss.2008.07.043. Epub 2008 Sep 4.